Publication Topic

Shah F, Hashimoto T, Segall MD, Greene N. 2014. Finding the rules for successful drug optimization. Drug Discov Today 18(13-14):659-666; doi: 10.1016/j.drudis.2014.01.005.

Davis PA, Wiegers TC, Roberts PM, King BL, Lay JM, Lennon-Hopkins K, Sciaky D,…, Greene N, et al. 2013. A CTD–Pfizer collaboration: Manual curation of 88 000 scientific articles text mined for drug–disease and drug–phenotype interactions. Database 2013(Nov 28):bat080; doi: 10.1093/database/bat080. PMID: 24288140.

Greene N, Gosink M. 2013. Computational toxicology experience and applications for risk assessment in the pharmaceutical industry. Chapter 10 in: Fowler BA (ed), Computational Toxicology: Methods and Applications. Elsevier-Academic Press, pp. 171-193; doi: 10.1016/B978-0-12-396461-8.00012-9.

Naven RT, Swiss R, Klug-McLeod J, Will Y, Greene N. 2013. The development of structure-activity relationships for mitochondrial dysfunction: Uncoupling of oxidative phosphorylation. Toxicol Sci 131(1):271-278; doi: 10.1093/toxsci/kfs279. PMID: 22977170.

Monticello TM, Bussiere JL. 2012. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton: CRC Press-Taylor and Francis Group, pp. 25-54.

Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. 2012. U.S. payer perspectives on evidence for formulary decision-making. J Oncol Pract 8(3 Suppl):22s-27s; doi: 10.1200/JOP.2011.000526. PMID: 22942820.

Boyer S, Muthas D, Greene N. 2011. Information, informatics and modeling in predictive toxicology. Chapter 5 in: Wilson AG, Rotella D, (eds), New Horizons in Predictive Toxicology: Current Status and Application. RSC Drug Discovery Series, Vol. 12. Royal Society of Chemistry Publishing, pp. 70-100; doi: 10.1039/9781849733045-00070.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, October 2011.

Greene N, Song M. 2011. Predicting in vivo safety characteristics using physicochemical properties and in vitro assays. Fut Med Chem 3(12):1503-1511; doi: 10.4155/fmc.11.89. PMID: 21882943.

Collins N. Preladenant: Preclinical development case study. Early Development Course: A Merck Polytechnic Institute Premier Course, Princeton, NJ, 2011.

Greene N, Aleo MD, Louise-May S, Price DA, Will Y. 2010. Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorg Med Chem Lett 20(17):5308-5312; doi: 10.1016/j.bmcl.2010.06.129. PMID: 20655216.

Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. 2010. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23(7):1215-1222; doi: 10.1021/tx1000865. PMID: 20553011.

Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Catalano J, Carl K, Charlab C,…, Robison TW, et al. 2010. Voluntary exploratory data submissions to the US FDA and the EMA: Experience and impact. Nat Rev Drug Discover 9(6):435-45; doi: 10.1038/nrd3116. PMID: 20514070.

Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, …, Collins N, et al. 2010. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 28(5):446–454; doi: 10.1038/nbt.1634. PMID: 20458314.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2009.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2008.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2007.

Burns AM, Woods CG, Rusyn I. Regulation of the mevalonate pathway influences proliferative effects of Wy-14,643 in mouse liver. Abstract 864, Society of Toxicology 46th Annual Meeting Charlotte, NC, March 2007.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, September 2006.

Rose WC, Marathe PH, Jang G, Monticello TM, Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y. PMID: 16228206.